A Placebo Controlled Double-Blind Study to Evaluate the Efficacy of Vismodegib as Chemoprevention of New Bcc Development in High Risk Subjects
Phase of Trial: Phase II
Latest Information Update: 28 May 2016
At a glance
- Drugs Vismodegib (Primary)
- Indications Basal cell cancer
- Focus Therapeutic Use
- 20 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 16 Oct 2015 Planned End Date changed from 1 Feb 2016 to 1 Jul 2016 as reported by ClinicalTrials.gov.
- 16 Oct 2015 Planned primary completion date changed from 1 Feb 2016 to 1 Dec 2015 as reported by ClinicalTrials.gov.